Volume 31, Number 1—January 2025
Research
Population-Based Study of Emergence and Spread of Escherichia coli Producing OXA-48–Like Carbapenemases, Israel, 2007–2023
Elizabeth Temkin
, Moshe Bechor, Mor N. Lurie-Weinberger, Alona Keren-Paz, Dafna Chen, Carmela Lugassy, Ester Solter, Mitchell J. Schwaber, Yehuda Carmeli, and CPE Working Group1
, Moshe Bechor, Mor N. Lurie-Weinberger, Alona Keren-Paz, Dafna Chen, Carmela Lugassy, Ester Solter, Mitchell J. Schwaber, Yehuda Carmeli, and CPE Working Group1
Table 1
Characteristics of 3,510 OXA-EC carriers, Israel, 2007–2023*
| Characteristic | No. (%) |
|---|---|
| Sex | |
| M | 1,936 (55.1) |
| F | 1,556 (44.3) |
| Not recorded |
18 (0.5) |
| Site where OXA-EC was first detected | |
| Rectal screening culture | 3,356 (95.6) |
| Clinical culture |
154 (4.4) |
| Nosocomial acquisition |
1,661 (47.3) |
| Sites of nosocomial acquisition | |
| Acute care hospital | 1,378/1,661 (83.0) |
| Internal medicine ward | 447/1,378 (32.4) |
| Surgical ward | 416/1,378 (30.2) |
| Intensive care unit | 134/1,378 (9.7) |
| Other | 381/1,378 (27.6) |
| Non–acute care setting | 283/1,661 (17.0) |
| Nursing home | 197/283 (69.6) |
| Post–acute care hospital | 76/283 (26.9) |
| Other | 10/283 (3.5) |
*OXA-EC, Escherichia coli producing OXA-48–like carbapenemases.
1Members of the working group are listed at the end of this article.
Page created: December 02, 2024
Page updated: December 22, 2024
Page reviewed: December 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.